anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To develop and validate a novel Comorbidity score for Robotic Surgery (CRS) in predicting severe complications after robot-assisted radical prostatectomy (RARP). Furthermore, we investigated the impact of the surgical platform (Multi-Port - MP vs Single-Port - SP) according to this score. We included 2085 ("development cohort") and 595 ("validation cohort") patients undergoing RARP at two tertiary referral centers between 2014 and March 2024 in a retrospective study. Statistical analyses included validation of the Charlson Comorbidity Index (CCI) to predict 30-day severe complications (Clavien-Dindo ≥ 3a), development and external validation of CRS using calibration plots and decision curve analysis. Lastly, locally weighted scatterplot smoothing (LOWESS) analysis was used to graphically explore the impact of the robotic platform according to novel CRS. CCI exhibited limited predictive ability for severe complications (60% in the validation cohort). In multivariable logistic regression analyses testing the correlation between each condition included in CCI and severe complications, diabetes and myocardial infarction resulted as independent predictors (OR 1.75 [95%CI 1.05-2.82]; OR 1.92 [95%CI 1.26-2.88]) and were subsequently fitted into a multivariable logistic model including age, previous abdominal surgery and obesity (BMI > 30). The resulting predictive model demonstrated superior discrimination and clinical net benefit in predicting severe complications compared to CCI (AUC 64 vs 60%). At LOWESS analysis, SP platform was associated with lower risk of severe complications as CRS increased compared to MP system. The validated CRS showed better accuracy compared to CCI in predicting severe complications after RARP. Additionally, the use of SP robotic platform may reduce the risk of severe complications in highly comorbid patients according to CRS.
PURPOSE:To obtain a skin external preparation presenting melanogenesis- inhibitory activity, having excellent effects on skin beautification and color fading for pigmentation after sunburn, spots, freckles, chloasma etc., also excellent in safety. CONSTITUTION:This skin external preparation contains an extract from Bardo (botanical name: Penumus boldus). The extract is obtained by immersing the whole parts of Bardo such as leaves, stems and fruits in or heat refluxing them with an extractant solvent followed by filtration and then concentrate the filtrate. The solvent is an organic solvent such as an alcohol, hydrous alcohol, acetone or ethyl acetate. The content of the extract in the whole external preparation is 0.005-20.0 (pref. 0.01-10.0)wt.% on a dry basis. This skin external preparation can be formulated, besides the aforementioned essential ingredient, with ingredients conventionally used in skin external preparations such as cosmetics and medicines (e.g. beautifier, humectant, antioxidant), where appropriate, at one's discretion.
Before the intervention, the students will be asked to rub the area around the area to be pressed for 20-30 seconds with their palms. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in the area of warming, relaxing and preparatory will be reduced and the tissue will be relieved. After rubbing, each individual's pain threshold level will be taken as a basis in order not to cause tissue damage. The students will be asked to press the designated point manually with their thumb, index or middle finger for 5 seconds with a depth of 1-1.5 cm, rest for 2 seconds and continue the practice for 2 minutes. In the study group, an average of 13 minutes will be applied to HT7, LI4 and EX-HN3 points (five points in total) for two minutes each. The nursing students participating in the research will be given a total of 12 acupressure intervention remotely, three days a week, for four weeks, at least two hours after dinner and when they are calmest.
Patients, who suffer from severe chronic intestinal failure and whose nutritional intake cannot be met by oral food intake, have as their final option total parenteral nutrition, which contains all necessary macro- and micronutrients. Lipid emulsions are essential for these patients as they are a source of non glucose fuel calories, and they contain (essential) fatty acids which are important as structural component for many cells in the human body. Home parenteral nutrition patients are at risk for essential fatty acid deficiency. Data are lacking that indicate the optimal amount of essential fatty acids required for these patients. The latter seems especially relevant for patients receiving lipid prescriptions which are low in essential fatty acids, like ClinOleic®. Long-term parenteral nutrition dependent patients successfully use ClinOleic®. It is however unknown whether these patient remain to have an adequate essential fatty acid status in the long run.
PROBLEM TO BE SOLVED: To handle an implant easily and reliably in a sterile condition by structuring by fixing an adapter by a lock screw and a central screw in an implant and fitting into a ratchet inserter where a screwdriver fitting into an entraining element and engaging with the central screw is arranged. SOLUTION: A central hole is provided in an adapter 6 screwed into an implant 1, and a central screw 8 is arranged, and the central screw 8 is inserted into the threaded hole 5 of a lock screw 4. A strip provided projectingly at the end face of the adapter 6 is engaged with an entraining groove of the implant 1 for nonrotatable fitting and connection. A sterile implant 1 before embedded, is grasped by a ratchet insert 23 and an internal pipe 16 is pulled out. The ratchet insert 23 having a contour 24 engaging with a ratchet key is connected to the adapter 6 in a fashion of fitting and interlocking. Thus the dental implant can be handled sterilely easily and reliably.
The target level for TSH suppression in these conditions has not been established with controlled studies. In addition, the efficacy of TSH suppression for benign nodular disease is controversial. Therefore, the dose of levothyroxine sodium tablets used for TSH suppression should be individualized based on the specific disease and the patient being treated.

In the treatment of well differentiated (papillary and follicular) thyroid cancer, levothyroxine is used as an adjunct to surgery and radioiodine therapy. Generally, TSH is suppressed to < 0.1 mU/L, and this usually requires a levothyroxine sodium dose of greater than 2 mcg/kg/day. However, in patients with high risk tumors, the target level for TSH suppression may be < 0.01 mU/L.

In the treatment of benign nodules and nontoxic multinodular goiter, TSH is generally suppressed to a higher target (e.g., 0.1 to 0.5 mU/L for nodules and 0.5 to 1.0 mU/L for multinodular goiter) than that used for the treatment of thyroid cancer. Levothyroxine sodium is contraindicated if the serum TSH is already suppressed due to the risk of precipitating overt thyrotoxicosis (see CONTRAINDICATIONS, WARNINGS and PRECAUTIONS).
This is a double-blind, placebo-controlled, research study to evaluate the effectiveness and safety of the experimental compound OP2000 (deligoparin) in patients with active ulcerative colitis. Patients eligible for this study will have received (and will continue to receive) stable doses of aminosalicylates (oral, enema and/or suppository), if tolerated. OP2000 is an ultra low molecular weight heparin with anticoagulant (blood thinning) and anti-inflammatory actions that may be of benefit for the treatment of ulcerative colitis. Patients will be randomized (assigned by chance like the toss of a coin) to receive 75 mg OP2000, 125 mg OP2000, or placebo once daily for 6 weeks. Study drug will be administered by subcutaneous (under the skin) injection and patients will be taught how to self-administer these injections. Following an initial Screening Visit, eligible patients will return to the clinic for initiation of study treatment and then again for follow-up visits after 1, 2, 4 and 6 weeks of treatment. A follow-up telephone call will be scheduled 2 months (and possibly also 4 and 6 months) after completing study treatment. Study procedures will include a flexible sigmoidoscopy at the Screening Visit and at the Week 6 visit.
PURPOSE:To obtain the subject compound useful as a synthetic intermediate for penem compounds known as agents for the treatment of microbism by reacting a penem allyl derivative with an allyl receptor in the presence of a bivalent palladium salt and its reducing agent. CONSTITUTION:The compound of formula III (R<3a> is H or acetoxymethyl) is produced by reacting a compound of formula I (R<1> is H or hydroxyl-protecting group; R<2> is organic group) with an allyl acceptor in the presence of a bivalent palladium salt (e.g. palladium acetate) and its reducing agent (e.g. triethyl phosphite) in a solvent (e.g. THF-methylene chloride) at -20 to +50 deg.C, optionally reacting the obtained compound of formula II or its salt with a halogenomethylacetal and optionally removing the protecting groups from the product. The allyl acceptor is e.g. 2-alkylhexanoic acid alkali metal salt.
Background and Objectives: The aim of this study is to evaluate the clinical and laboratory changes of ischemia and reperfusion injury in the remnant livers of donors with and without Pringle maneuver. Furthermore, we evaluated the recipients who have been transplanted with liver grafts from these donors. Methods and Materials: A total of 108 patients (54 living liver donors and 54 liver recipients) who underwent donor hepatectomy and recipients who living donor liver transplantation, were included in this randomized double-blind study between February 2021 and June 2021. The donors were divided into two groups: Pringle maneuver applied (n = 27) and Pringle maneuver not applied (n = 27). Similarly, recipients with implanted liver obtained from these donors were divided into two groups as the Pringle maneuver was performed (n = 27) and not performed (n = 27). Blood samples from donors and recipients were obtained on pre-operative, post-operative 0 h day (day of surgery), post-operative 1st day, post-operative 2nd day, post-operative 3rd day, post-operative 4th day, post-operative 5th day, and liver tissue was taken from the graft during the back table procedures. Liver function tests and complete blood count, coagulation tests, IL-1, IL-2, IL-6, TNF-α, and β-galactosidase measurements, and histopathological findings were examined. Results: There was no statistically significant difference in the parameters of biochemical analyses for ischemia-reperfusion injury at all periods in the donors with and without the Pringle maneuver. Similarly, there was no statistically significant difference between in the recipients in who received liver grafts harvested with and without the Pringle maneuver. There was no statistically significant difference between the two recipient groups in terms of perioperative bleeding and early bile duct complications (p = 0.685). In the histopathological examinations, hepatocyte damage was significantly higher in the Pringle maneuver group (p = 0.001). Conclusions: Although the histological scoring of hepatocyte damage was found to be higher in the Pringle maneuver group, the Pringle maneuver did not augment ischemia-reperfusion injury in donors and recipients that was evaluated by clinical and laboratory analyses.
Photodynamic Therapy (PDT) has gained popularity as an effective, non-scarring treatment for thin, non-hyperkeratotic actinic keratoses (AKs). Similar to the topical agents 5-fluorouracil and imiquimod, PDT is particularly useful when utilized as a field-directed therapy for the treatment of areas with multiple AKs and extensive sun damage. PDT consists of two steps: 1) the topical application of a photosensitizer agent aminolevulinic acid (ALA), which is preferentially converted to the photosensitive protoporphyrin IX (PpIX) in precancerous and neoplastic cells, and 2) controlled exposure to a visible wavelength light source. Current methodologies utilize a "one-size-fits-all" approach with regard to duration of incubation with photosensitizing agents and illumination. Moreover, patients frequently experience pain after long PDT prodrug incubation. Better characterization of photosensitization in PDT can help tailor incubation and overall treatment time to minimize treatment duration and discomfort while maximizing clearance of the target lesions. The direct measurement of PpIX is a promising, yet rarely performed test that may help determine the appropriate PDT treatment time, the need for re-treatment or adjuvant therapy, and potential efficacy of treatment. Point-probe measurements have shown extreme heterogeneity between PpIX levels in different patients and among different lesions in the same patient. However, these point-probe measurements are unable to account for the variance in PpIX production in different parts of the skin because of their relatively limited field of view. The recent development of a low-cost, smart phone-based, wide-field fluorescence dosimetry imaging system to map PpIX levels onto a 2D image allows for handheld, real-time analysis of PpIX levels in human skin. Initial unpublished clinical results have shown its utility in human subjects. However, a more extensive characterization of the factors that influence baseline in PpIX has yet to be performed. This study intends to elaborate these inter-and intra-individual variances, including analysis of changes in PpIX concentrations based on anatomical location, age, diet, temperature, pigmentation, and previous skin damage.
The utility model discloses Chinese herbal medicine set tablets for outer application, which comprises an outer ring table, a middle ring table and a core table which comprises different medicine prepared according to the dialectical therapeutic principle of traditional Chinese medicine. The outer surfaces of the outer ring table, the middle ring table and the core table are provided with layers of medical osmotic membranes of polymer materials. The size of the core table is corresponding to the inner ring of the middle ring table, the size of the middle ring table is corresponding to the inner ring of the outer ring table, and the Chinese herbal medicine set tablets for outer application is formed by the outer ring table, the middle ring table and the core table. Since the ring tables with different diameters represent the prescriptions with different dialectical types, the utility model can change the medicine of the ring table according to the physical circumstances of patients. The personalized and rationalized treatment is achieved. The Chinese herbal medicine set tablets for outer application can be directly applied to the acupoints of a human body, and the medicine is transdermic administrated. The first pass effect of the liver and the interfering and degrading effects of the alimentary facts are avoided. The utility model has no side effect, and the effect is better. The Chinese herbal medicine set tablets for outer application is particularly suitable for infants, senile patients, patients who can not eat the medicine because of the emesis, and patients who use medicine chronically.
This group will consist of up to 10 people who are on a regular infusing cycle of 28-30 days who will be transitioning to an extended dosing cycle. The decision to transition will be made by their treating neurologist. These participants will be consented at Week 0 (Baseline) and will be followed for 8 cycles. Natalizumab concentration will be measured at each cycle. During certain cycles, other biomarkers will be measured.
Behavioral/lifestyle interventions produce acceptable success in treating moderately obese subjects. However, their effectiveness on weight loss and maintenance in morbidly obese subjects remains elusive.

Twenty-nine morbidly obese females participated in this non-randomized study. Fifteen subjects were assigned to the lifestyle group and 14 underwent vertical banded gastroplasty. Subjects in the lifestyle group attended 30 behavioral modification sessions over three years, whereas the surgery group received the standard of care nutrition. Body weight, resting metabolic rate, physical activity, body composition measurements and dietary intake data were assessed at standard time points during the first 3 years post-intervention. Follow-up data on body weight and physical activity were also collected 9 years later.
Clostridium difficile is the most frequent bacterial cause of antibiotic-associated diarrhea. Those with a previous C. difficile infection (CDI) are at high risk of recurrent infection. Recurrent CDI often occurs when the normal gut microbiota are disrupted. Dysbiosis of the gut microbiota predisposes to CDI which, despite treatment can recur in 30% of patients. A novel way to prevent CDI recurrence is by instilling feces from a healthy individual into the intestine of the CDI patient, thereby restoring balance in the gut microbiota. However, it is unknown whether or not fecal microbiota transplantation (FMT) is an efficacious choice for CDI recurrence prevention when used concurrently with antibiotics. We propose a pilot randomized, double-blind placebo controlled trial comparing oral FMT with placebo in patients with a history of CDI, currently undergoing antibiotic treatment. We will collect fecal samples from subjects prior to, during, and after FMT and collect metagenomics and microbiologic data on microbiota composition and function, and CDI recurrence. The trial's primary outcome is gut microbial composition and function. Secondary outcomes are feasibility and safety, and recurrent CDI during the trial period. In this 3 group study, FMT will be administered daily via oral capsules containing frozen fecal microbiota from universal donors in group 1, administered at the end of antibiotic treatment for group 2, and group 3 will receive daily placebo. The results of this study will provide the necessary pilot data to examine whether or not concurrent FMT in antibiotic treated patients who are at high risk for recurrent CDI can maintain a diverse healthy GI microbiota.
Colorectal cancer (CRC) is the second leading cause of cancer mortality in the US. CRC's risk is closely linked to the modern lifestyle. Alcohol is commonly used in our society and is an established risk factor for both pre-cancerous (polyp) and cancerous lesions of the colon. However this knowledge has not been translated to our current risk stratifications for CRC as the process of alcohol-induced carcinogenesis is not predictable. Mucosal inflammation is a well-established mechanism that mediates the effect of alcohol induced tissue injury in the intestine. Inflammation also plays a crucial role in pathogenesis of CRC. Factors that promote a pro-tumorigenic inflammatory state in the setting of alcohol are unknown. Since CRC occurs only in a small subset of alcohol user, alcohol alone may not be sufficient to start the neoplastic process and additional cofactors are required. One such factor is circadian dysrhythmia that is another modern lifestyle habit, shown to be associated with an increased risk of CRC. Further, previous research has shown that disruption of circadian rhythm exacerbates alcohol-induced intestinal inflammation. The Investigator hypothesize that altered circadian rhythms due to "wrong-time" eating (abnormal eating) are an important determinant in alcohol induced mucosal inflammation and carcinogenesis. Our preliminary data supports our hypothesis and shows that abnormal eating patterns accelerate alcohol-induced polyposis in a mouse model of CRC. Each subject will experience four conditions (each for one week in duration with a week +/- 2 days wash-out in between): (1) "right-time eating" / no alcohol, (2) "right-time eating" / with alcohol, (3) "delayed-eating" / no alcohol, (4) "delayed-eating" / with alcohol. The order of experiments will be randomized \[concealed randomization\]. All subjects will undergo unprepped sigmoidoscopy after each week of intervention. In Aim 2, all subjects will have an option to undergo a 24h circadian assessment in the Biological Rhythms Research Lab after each week of intervention. The Investigator will assess (i) central circadian rhythms by collecting hourly salivary samples for melatonin assays and (ii) peripheral rhythm in the intestinal tract by buccal swabs once every 2h (12 time points) as well as by rectal sampling twice (every 12 hr). For Aim 3, sigmoidoscopy without sedation will be used to obtain colonic samples as the safe method compared to colonoscopy, which has some small but finite risks associated with the procedure (e.g, bleeding or perforation) as well as sedation.
BACKGROUND: Suicide behavior represents a major public health problem for the older population. Within the continuum of suicidal behavior, suicidal ideation may lead to a suicide attempts/death. Risk factors for developing suicidal ideation include mobility limitations, lack of social participation and loneliness. However, there is a need for longitudinal studies to examine these relationships over time.
METHOD: 50423 older people from three waves of the SHARE project formed the sample (60 years in the first wave; M ± SD = 71.49 ± 8.15; 55% female).
RESULTS: A series of nested Cross-Lagged Panel Models (CLPM) of suicidal ideation, mobility limitations, social participation and loneliness were tested. The best fitting model was that with equal autoregressive and cross-lagged effects across waves (χ² = 1220.56, CFI = .982, RMSEA = .028, SRMR = .024). The autoregressive effects showed high stability across waves. The cross-lagged effects between suicidal ideation and mobility limitations were strong, while the cross-lagged effects between suicidal ideation and social participation were comparatively smaller. In the case of loneliness, statistical significance was not achieved.
CONCLUSIONS: These findings highlight the importance of promoting mobility programs and social activities to prevent suicidal ideation among older adults.
1284545 Opaque toothpastes COLGATEPALMOLIVE CO 4 Aug 1969 [5 Aug 1968 (2)] 10834/72 Divided out of 1284544 Heading A5B An opaque toothpaste has dispersed therein particles of agglomerated solid toothpaste ingredient comprising a water-insoluble dental polishing agent e.g. dicalciumphosphate, sodium metaphosphate, calcium carbonate, hydrated alumina, zirconium silicate, or various other phosphates, MgCO 3 , SiO 2  aluminium silicate or polymethyl methacrylate; which agglomerated particles are visible to the naked eye (preferably of size less than 2380 microns) and palpable and substantially retain their identity in the toothpaste and in the presence of saliva but are easily reducible by toothbrushing to fine, impalpable individual particles of the ingredient each of which is invisible to the naked eye (e.g. of size less than 177 microns). The polishing agent is blended with a binding agent e.g. polyethylene glycol, gum acacia, or polyvinyl pyrrolidone, and this blend or a blend of polishing and tabletting agents may be compressed into tablets which are then broken down into the agglomerated particles. The agglomerates may be coloured by a dye or pigment and are incorporated into the toothpaste base which may be a gelled dental vehicle typically comprising e.g. 20- 50% liquid and 0.5-5% gelling agent or gum, by weight of the toothpaste. The liquid portion comprises e.g. water, glycerine, sorbitol solution, propylene glycol or polyethylene glycol. Conventional additives may also be present in the toothpaste.
Healthy controls Participants will receive COVID19 vaccination according to standard of care (any FDA approved vaccine). They will donate serial biospecimens before and after vaccination according to the study design.